Sugi Predict

Sugi Predict / Compounds / SCHEMBL10141773

SCHEMBL10141773

SCHEMBL10141773

C[C@H]1CC[C@H]2[C@H](C1)C1=C(OC2(C)C)c2ccccc2C(=O)C1=O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABCB1 P08183 1/20 0.69
▸ NQO1 P15559 6/20 0.43
▸ IDO1 P14902 11/20 0.42
▸ KDM4E B2RXH2 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ CES2 O00748 1/20 0.39
▸ GMNN O75496 1/20 0.39
▸ TDP2 O95551 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ GLA P06280 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ HSPD1 P10809 1/20 0.39
▸ THRB P10828 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10142037 1.00 ABCB1 (0.69) ABCB1NQO1IDO1KDM4EMEN1
SCHEMBL103949 0.75 IDO1 (0.53) NQO1IDO1KDM4EMEN1CES2
SCHEMBL18791100 0.71 IDO1 (0.55) NQO1IDO1KDM4EMEN1CES2
SCHEMBL20811248 0.71 IDO1 (0.59) NQO1IDO1KDM4EMEN1CES2
SCHEMBL16692248 0.69 ABCB1 (0.49) ABCB1KDM4EALDH1A1
SCHEMBL17193493 0.69 ABCB1 (0.49) ABCB1KDM4EALDH1A1
SCHEMBL18791133 0.69 IDO1 (0.63) NQO1IDO1KDM4EMEN1CES2
SCHEMBL20811039 0.66 NQO1 (0.76) NQO1IDO1KDM4EMEN1CES2
SCHEMBL15359117 0.66 ABCB1 (0.59) ABCB1
SCHEMBL15359120 0.66 ABCB1 (0.59) ABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2655344-B1 NOVEL PHENAZINE DERIVATIVES AND THEIR USE UNIV CATHOLIQUE LOUVAIN (BE) 2015-11-25 — — EP disclosed
US-9181265-B2 Substituted 2,3-dihydro-1H-benzo[a]pyrano[2,3-c]phenazines as anti-angiogenic and anti-cancer agents UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) 2015-11-10 — — US disclosed
US-9181265-B2 Substituted 2,3-dihydro-1H-benzo[a]pyrano[2,3-c]phenazines as anti-angiogenic and anti-cancer agents UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) 2015-11-10 — — US disclosed
US-20130289030-A1 NOVEL PHENAZINE DERIVATIVES AND THEIR USES UNIVERSITE LIBRE DE BRUXELLES (BE) 2013-10-31 — — US disclosed
US-20130289030-A1 NOVEL PHENAZINE DERIVATIVES AND THEIR USES UNIVERSITE LIBRE DE BRUXELLES (BE) 2013-10-31 — — US disclosed
WO-2012085222-A1 NOVEL PHENAZINE DERIVATIVES AND THEIR USE UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) 2012-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130289030-A1 NOVEL PHENAZINE DERIVATIVES AND THEIR USES VEGFA, KDR, FLT4 ABCB1 108/4885NQO1 1052/4885IDO1 2619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.